Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial

Open access

Abstract

Background Women with polycystic ovary syndrome (PCOS) have an increased risk of pregnancy complications. Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group. The aim of this third randomised trial (PregMet2) was to test the hypothesis that metformin prevents late miscarriage and preterm birth in women with PCOS.Methods PregMet2 was a randomised, placebo-controlled, double-blind, multicentre trial done at 14 hospitals in Norway, Sweden, and Iceland. Singleton pregnant women with PCOS aged 18-45 years were eligible for inclusion. After receiving information about the study at their first antenatal visit or from the internet, women signed up individually to participate in the study. Participants were randomly assigned (1:1) to receive metformin or placebo by computer-generated random numbers. Randomisation was in blocks of ten for each country and centre; the first block had a random size between one and ten to assure masking. Participants were assigned to receive oral metformin 500 mg twice daily or placebo during the first week of treatment, which increased to 1000 mg twice daily or placebo from week 2 until delivery. Placebo tablets and metformin tablets were identical and participants and study personnel were masked to treatment allocation. The primary outcome was the composite incidence of late miscarriage (between week 13 and week 22 and 6 days) and preterm birth (between week 23 and week 36 and 6 days), analysed in the intention-to-treat population. Secondary endpoints included the incidence of gestational diabetes, preeclampsia, pregnancy-induced hypertension, and admission of the neonate to the neonatal intensive care unit. We also did a post-hoc individual participant data analysis of pregnancy outcomes, pooling data from the two previous trials with the present study. The study was registered with ClinicalTrials.gov, number NCT01587378, and EudraCT, number 2011-002203-15.Findings The study took place between Oct 19, 2012, and Sept 1, 2017. We randomly assigned 487 women to metformin (n=244) or placebo (n=243). In the intention-to-treat analysis, our composite primary outcome of late miscarriage and preterm birth occurred in 12 (5%) of 238 women in the metformin group and 23 (10%) of 240 women in the placebo group (odds ratio [OR] 0·50, 95% CI 0·22-1·08; p=0·08). We found no significant differences for our secondary endpoints, including incidence of gestational diabetes (60 [25%] of 238 women in the metformin group vs 57 [24%] of 240 women in the placebo group; OR 1·09, 95% CI 0·69-1·66; p=0·75). We noted no substantial between-group differences in serious adverse events in either mothers or offspring, and no serious adverse events were considered drug-related by principal investigators. In the post-hoc pooled analysis of individual participant data from the present trial and two previous trials, 18 (5%) of 397 women had late miscarriage or preterm delivery in the metformin group compared with 40 (10%) of 399 women in the placebo group (OR 0·43, 95% CI 0·23-0·79; p=0·004).Interpretation In pregnant women with PCOS, metformin treatment from the late first trimester until delivery might reduce the risk of late miscarriage and preterm birth, but does not prevent gestational diabetes.Funding Research Council of Norway, Novo Nordisk Foundation, St Olav's University Hospital, and Norwegian University of Science and Technology.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30002-6

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 33 references

Cited by

See all 176

Metadata

Authors
Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., Trouva, A., Thorarinsdottir, S., Hjelle, S., Berg, A. H., Andræ, F., Poromaa, I. S., Mohlin, J., Underdal, M., & Vanky, E.
Affiliations
  • Norwegian University of Science and Technology (NO)
  • National University Hospital of Iceland (IS)
  • Umeå University (SE)
  • Haukeland University Hospital (NO)
  • Vestre Viken Hospital Trust (NO)
  • Sykehuset i Vestfold (NO)
  • Karolinska University Hospital (SE)
  • Uppsala University (SE)
  • Telemark Hospital (NO)
  • Ålesund Hospital (NO)
  • Innlandet Hospital Trust (NO)
  • Nordland Hospital Trust (NO)
  • Stockholm South General Hospital (SE)
Corresponding author
Løvvik, Tone S
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2019-04
Volume
7
Issue
4
Pages
256-266
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2916534006
Cited by
176
References
33
Citations by year
2026: 22 · 2025: 17 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 27 · 2020: 17 · 2019: 9
FWCI
20.08
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • DiVA at Umeå University (Umeå University) (submittedVersion, other-oa)
  • Hirsla (Landspítali University Hospital) (submittedVersion)
Funders
  • Novo Nordisk Fonden
  • St. Olavs Hospital Universitetssykehuset i Trondheim
  • Norges Teknisk-Naturvitenskapelige Universitet
  • Norges Forskningsråd
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
polycystic ovary syndrome, pregnancy, late miscarriage, preterm birth, gestational diabetes mellitus, preeclampsia, gestational hypertension, neonatal intensive care admission, individual patient data meta-analysis, pregnancy outcomes
MeSH terms
Abortion, Spontaneous, Adolescent, Adult, Blood Glucose, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Iceland, Infant, Newborn, Metformin, Middle Aged, Norway, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Prognosis, Sweden, Biomarkers, Incidence, Diabetes, Gestational, Premature Birth, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30002-6
The paper
Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., Trouva, A., Thorarinsdottir, S., Hjelle, S., Berg, A. H., Andræ, F., Poromaa, I. S., Mohlin, J., Underdal, M., & Vanky, E. (2019). Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30002-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.